Drug intelligence / Profile preview

HH102

Development stage: Preclinical
Lead developer: Hedgehog Co.
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

HH102 is a monoclonal antibody targeting the Eph receptor B3 (EPHB3), currently under development by Hedgehog Technology for the treatment of solid cancers. EPHB3 is a receptor tyrosine kinase involved in cell-cell communication and signaling pathways that are often dysregulated in various malignancies. HH102 functions by competitively inhibiting the interaction between the EPHB3 receptor and its ephrin ligands, thereby modulating Eph receptor signaling to suppress tumor growth and progression. As of early 2024, the drug is in the discovery/hit stage of preclinical development.

Targets

EPHB3

Beyond the preview

Go deeper on HH102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HH102.

Explore the full profile